The inhibitor was able to reduce the viability of multiple TP53 wild-type cell lines, including several hematologic cancers, and MYCN amplified NB cell lines, as well as a subset of TP53 mutant cell lines [186]. This evidence concerns the gene TP53 and neuroblastoma.